You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Boehringer Ingelheim
AstraZeneca
Colorcon

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

PYRIDOSTIGMINE BROMIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Pyridostigmine Bromide, and when can generic versions of Pyridostigmine Bromide launch?

Pyridostigmine Bromide is a drug marketed by Amneal Pharms Llc, Invatech, Novitium Pharma, Alvogen, Impax Labs Inc, Rising, Ani Pharms Inc, Elysium, Impax Labs, Solvay, Us Army, and Zydus Pharms. and is included in thirteen NDAs.

The generic ingredient in PYRIDOSTIGMINE BROMIDE is pyridostigmine bromide. There are eleven drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the pyridostigmine bromide profile page.

US ANDA Litigation and Generic Entry Outlook for Pyridostigmine Bromide

A generic version of PYRIDOSTIGMINE BROMIDE was approved as pyridostigmine bromide by IMPAX LABS on April 24th, 2003.

  Start Trial

Drug patent expirations by year for PYRIDOSTIGMINE BROMIDE
Recent Clinical Trials for PYRIDOSTIGMINE BROMIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranPhase 2/Phase 3
Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranPhase 2
Vanderbilt University Medical CenterPhase 1

See all PYRIDOSTIGMINE BROMIDE clinical trials

Pharmacology for PYRIDOSTIGMINE BROMIDE
Medical Subject Heading (MeSH) Categories for PYRIDOSTIGMINE BROMIDE

US Patents and Regulatory Information for PYRIDOSTIGMINE BROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms Llc PYRIDOSTIGMINE BROMIDE pyridostigmine bromide SYRUP;ORAL 212702-001 Jan 10, 2020 AA RX No No   Start Trial   Start Trial   Start Trial
Ani Pharms Inc PYRIDOSTIGMINE BROMIDE pyridostigmine bromide TABLET;ORAL 040512-002 Jul 20, 2005 DISCN No No   Start Trial   Start Trial   Start Trial
Alvogen PYRIDOSTIGMINE BROMIDE pyridostigmine bromide TABLET, EXTENDED RELEASE;ORAL 204737-001 Jun 26, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Impax Labs Inc PYRIDOSTIGMINE BROMIDE pyridostigmine bromide TABLET;ORAL 040457-001 Dec 26, 2002 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
McKinsey
Merck
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.